Click the link below the picture
.
Take Aways
- MIT researchers engineered M13 bacteriophage particles to control how densely they display antigens, strengthening targeted immune responses in mice.
- Higher-density vaccines improved protection in melanoma and colorectal tumor-cell challenge experiments, with a roughly sevenfold higher fraction of neoantigen-specific T cells in the colorectal model.
- The platform could support personalized cancer vaccines, but this study vaccinated mice before tumor-cell injections and did not establish effectiveness in people.
Packing more cancer targets onto a tiny viral scaffold helped mice mount a stronger defense against injected tumor cells. The finding points to a controllable feature of vaccine design: how densely a delivery particle displays the molecular markers that immune cells learn to recognize. It could help researchers refine personalized cancer vaccines.
The MIT study, published in Advanced Healthcare Materials, uses an engineered bacteriophage called M13. Shengnan Huang, a research scientist at the Koch Institute for Integrative Cancer Research, led the work. Senior author Angela Belcher is MIT’s James Mason Crafts Professor of Biological Engineering and Materials Science and Engineering.
The results come from laboratory experiments and small mouse studies, not clinical trials. The work focused on improving the design of a vaccine formulation. Mice received vaccines before researchers injected tumor cells, testing protection against a later challenge. Whether the same density adjustments improve treatment of established tumors requires further testing.
Turning a bacterial virus into a vaccine carrier
M13 is a bacteriophage, a virus that infects bacteria rather than human cells. Its single-stranded DNA sits inside a long protein shell, or capsid. The engineered particles in this study measured approximately 200 nanometers in length.
The researchers attached antigens, molecular targets recognized by immune cells, to a major capsid protein called pVIII. Each particle contained a mixture of ordinary pVIII and antigen-bearing versions. Altering that mixture changed the density of antigen displayed along the particle’s surface.
The viral DNA also supplies an immune-stimulating signal through Toll-like receptor 9, or TLR9. That gives M13 its own adjuvant activity, helping amplify the response to its antigen cargo. Combining the target and this immune activation signal within one scaffold is part of the platform’s appeal.
Making antigen density adjustable
Huang first worked with SIINFEKL, a short peptide commonly used as a model antigen in mouse immunology. Adding negatively charged amino acids alongside it helped antigen-bearing proteins assemble into the capsid. Changing where the proteins were produced in the genetic system further altered their relative abundance.
The team also introduced a regulatory mutation that reduced production of the antigen-bearing protein. Together, these methods adjusted its proportion from about 6% to 70.4% of the major coat proteins. That corresponds to roughly 36 to 420 antigen-bearing copies per 200-nanometer particle.
The highest density came with a manufacturing drawback: particle yield fell substantially. A mutation lowered display to approximately 34.7% while improving production. The work therefore identified a trade-off between maximizing antigen display and producing enough stable particles for further development.
“The antigen is the specific target we want to initiate the immune response against, which means we have to ensure the right dose of antigen to make sure that we can have a strong immune response,” Huang says. Her explanation highlights why the team investigated both particle design and the resulting immune activity.
How immune cells handled the particles
The researchers compared particles carrying approximately 6% and 34.7% antigen-bearing coat proteins. In laboratory tests, dendritic cells took up the higher-density particles about 2.8 times more efficiently. These antigen-presenting cells help teach T cells which molecular targets to recognize.
Higher-density particles also improved antigen presentation, the display of processed peptide fragments on the immune cell’s surface. Comparable presentation required roughly half as much particle uptake with the denser version. This suggests that changing surface display affected more than the number of particles reaching a cell.
Not every immune measurement increased. The two versions produced similar results for a dendritic-cell activation marker and TLR9 activation, consistent with their identical DNA cargo. The precise reasons for the uptake and presentation differences remain unresolved, including possible effects on surface charge and intracellular processing.
The particles also remained structurally stable in the reported tests. Blood measurements in mice showed little induction of two inflammatory signals, IL-6 and TNF-alpha. Those limited findings support further development but cannot establish a vaccine’s safety in people or rule out other adverse effects.
Testing protection against later tumor challenges
Mice received equal numbers of the two particle types on days zero and seven. On day 15, researchers injected melanoma cells engineered to express SIINFEKL. The higher-density vaccine produced stronger protection, slower tumor progression and a larger fraction of antigen-specific CD8 T cells, which can attack matching tumor cells.
That T-cell fraction rose from approximately 7.4% to 17.5%. The reported melanoma experiments included five to six mice per group for key immune and tumor measurements. These findings add to research investigating how nanoparticle vaccines can prepare an immune response before tumor exposure.
The researchers then switched to a mutated ADPGK peptide found in the mouse colorectal cancer model MC-38. Such tumor-specific targets are called neoantigens. Increasing their display raised the neoantigen-specific CD8 T-cell fraction from approximately 1.1% to 7.4%, a roughly sevenfold increase.
After MC-38 cells were injected under the skin, the denser vaccine slowed tumor growth and prolonged survival. Median survival reached 38 days, compared with 28 days for the lower-density vaccine and 25.5 days without vaccination. Key analyses used six to eight mice per group; this was a colorectal cancer cell model, not spontaneous cancer prevention.
.
Artist’s illustration of antigen-coated M13 particles interacting with an immune cell. MIT researchers found that denser antigen displays strengthened targeted immune responses and improved tumor protection in mice vaccinated before exposure to cancer cells. (CREDIT: The Brighter Side of News)
.
.
Click the link below for the complete article:
.
__________________________________________
Leave a Reply